Ocular Therapeutix

OCULAR THERAPEUTIX INC

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

New,York,,Usa,-,17,February,2021:,Carnival,Corp,Logo

News

Intraday Update

Markets

Movers

Trading Ideas

AMBA

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

BBAI

COIN

COMM

New Oriental Education & Technology Group

GRRR

HOOD

LIMN

MBLY

MMYT

OCUL

PONY

RZLV

UBER

Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday

Eye.eyechart.ocular

Earnings

Health Care

Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results.

Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings

Initiation

Pre-Market Outlook

Analyst Ratings

SYRE

VNRX

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Ocular Therapeutix Inc

Oculis Holding AG

Oculus Inc

Press Releases

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

General

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Axsome Therapeutics

BGM Group

Belite Bio, Inc - American Depositary Shares

Belite Bio

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Innoviva

LENZ Therapeutics

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

HC Wainwright & Co.

Needham

RBC Capital

Citizens Capital Markets

Scotiabank

Comments

Ocular Therapeutix

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell